WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by. Presented ...

A major HIV drug maker will return $202 million nationwide after a multi-year investigation and settlement. Pharmaceutical ...

The WHO has approved the use of a new drug to prevent HIV. The drug is called Lenacapavir, and what makes it unique is that ...

A new kind of HIV prevention is making it easier for those at risk to stay protected, thanks to a twice-yearly injection now ...

Philippines called for a youth-centered response and preventive care to Human Immunodeficiency Virus (HIV) following a recent ...

Results from the Phase III PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) trials highlight Yeztugo’s (lenacapavir) ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...